Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients

This article was originally published here

In the study, 144 participants were randomized to receive either the vaccine or placebo to prevent recurrence. The vaccines were initiated within three months of completion of standard

The post Elios Therapeutics presents new Phase IIb data for personalized cancer vaccine in high-risk melanoma patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply